GlassScriptPhysician profile
Arthur L Lebowitz
NPI 1205851169
$16,666.39
in general payments reported to CMS, 2019-2025
40 companies · $2,401 in 2025
The $2,401 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,579 · 2020: $2,291 · 2021: $2,310 · 2022: $1,749 · 2023: $2,361 · 2024: $2,976 · 2025: $2,401.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,703 · Education: $35.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,702.59 |
| Education | $35.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,915.76 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $1,819.12 | 2019-2025 | Ozempic, Rybelsus |
| Bayer Healthcare Pharmaceuticals INC. | $1,749.60 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,512.82 | 2019-2025 | Jardiance |
| Pfizer INC. | $1,382.13 | 2019-2025 | |
| Lilly USA, LLC | $1,143.24 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $1,010.25 | 2019-2025 | Trintellix |
| Abbvie INC. | $914.65 | 2019-2025 | |
| Amarin Pharma, INC. | $911.98 | 2019-2021 | |
| Glaxosmithkline, LLC. | $661.02 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $562.32 | 2019-2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $513.25 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $444.06 | 2019-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $323.11 | 2019-2022 | |
| Allergan, INC. | $294.99 | 2019-2020 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $272.86 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $173.03 | 2019-2025 | Veozah, Myrbetriq |
| Arbor Pharmaceuticals, INC. | $155.28 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $135.01 | 2019-2024 | Eliquis |
| Kowa Pharmaceuticals America, INC. | $117.95 | 2020-2021 | |
| Eisai INC. | $90.31 | 2020-2022 | |
| Genentech USA, INC. | $58.99 | 2019-2021 | |
| Azurity Pharmaceuticals, INC. | $52.43 | 2025 | Edarbi |
| Medtronic, INC. | $50.48 | 2021 | |
| Almatica Pharma LLC | $42.64 | 2023 | Sertraline Hcl, Loreev Xr, Gralise |
| Otsuka America Pharmaceutical, INC. | $41.28 | 2023 | Rexulti |
| Sanofi-Aventis U.S. LLC | $35.67 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $35.56 | 2021-2022 | |
| Therapeuticsmd, INC. | $32.86 | 2019 | |
| Idorsia Pharmaceuticals US INC | $32.44 | 2023-2024 | Quviviq |
| Esperion Therapeutics, INC. | $26.10 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.02 | 2024 | Caplyta |
| Abbott Laboratories | $21.01 | 2023 | Freestyle Libre 3 |
| Sunovion Pharmaceuticals INC. | $19.53 | 2019 | |
| Intra-Sana Laboratories | $17.94 | 2025 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Xeris Pharmaceuticals, INC. | $17.60 | 2025 | Gvoke Hypopen |
| Ultragenyx Pharmaceutical INC. | $17.05 | 2021 | |
| Paratek Pharmaceuticals, INC. | $13.83 | 2024 | Nuzyra |
| Phathom Pharmaceuticals, INC. | $13.03 | 2025 | Voquezna |
| Radius Health, INC. | $12.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arthur Lebowitz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.